NGEN NASDAQ
NervGen Pharma Corp. Common stock
1W: -0.8%
1M: -8.7%
3M: -17.3%
YTD: -37.4%
$2.08
-1.60 (-43.48%)
Weekly Expected Move ±6.1%
$3
$3
$4
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$168.3M
52W Range1.5-6.3
Volume12,441,264
Avg Volume169,925
Beta0.88
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAdam H. Rogers
Employees7
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-08
Websitenervgen.com
1455 Bellevue Avenue, Suite 301
West Vancouver, BC V7T 1C3
CA
West Vancouver, BC V7T 1C3
CA
604-336-8089
About NervGen Pharma Corp. Common stock
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
Latest News
12 Health Care Stocks Moving In Friday's Intraday Session
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results
12 Health Care Stocks Moving In Friday's Pre-Market Session
Biggest stock movers Friday: WDAY, ZM, and more
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dreismann Heiner | A-Award | 59,524 | — | 2008-06-25 |
| SCHREIBER DAVID | A-Award | 59,524 | — | 2008-06-25 |
| BIRNDORF HOWARD C | A-Award | 547,500 | $0.42 | 2008-04-02 |
| Dreismann Heiner | A-Award | 18,116 | — | 2007-06-13 |
| SCHREIBER DAVID | A-Award | 18,116 | — | 2007-06-13 |